Literature DB >> 23785225

Role of apixaban (eliquis) in the treatment and prevention of thromboembolic disease.

Aliaksandr Budovich, Olga Zargarova, Anna Nogid.   

Abstract

Entities:  

Year:  2013        PMID： 23785225      PMCID： PMC3684191     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


× No keyword cloud information.
  24 in total

1.  Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients.

Authors:  Samuel Z Goldhaber; Alain Leizorovicz; Ajay K Kakkar; Sylvia K Haas; Geno Merli; Robert M Knabb; Jeffrey I Weitz
Journal:  N Engl J Med       Date:  2011-11-13       Impact factor: 91.245

Review 2.  The role of apixaban for venous and arterial thromboembolic disease.

Authors:  Rathasen Prom; Sarah A Spinler
Journal:  Ann Pharmacother       Date:  2011-09-27       Impact factor: 3.154

3.  Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a predefined subgroup analysis from AVERROES, a randomised trial.

Authors:  Hans-Christoph Diener; John Eikelboom; Stuart J Connolly; Campbell D Joyner; Robert G Hart; Gregory Y H Lip; Martin O'Donnell; Stefan H Hohnloser; Graeme J Hankey; Olga Shestakovska; Salim Yusuf
Journal:  Lancet Neurol       Date:  2012-02-01       Impact factor: 44.182

4.  Safety and efficacy of the oral direct factor xa inhibitor apixaban in Japanese patients with non-valvular atrial fibrillation. -The ARISTOTLE-J study-.

Authors:  Satoshi Ogawa; Yukito Shinohara; Kazuhiro Kanmuri
Journal:  Circ J       Date:  2011-06-14       Impact factor: 2.993

5.  Apixaban versus enoxaparin for thromboprophylaxis after hip replacement.

Authors:  Michael Rud Lassen; Alexander Gallus; Gary E Raskob; Graham Pineo; Dalei Chen; Luz Margarita Ramirez
Journal:  N Engl J Med       Date:  2010-12-23       Impact factor: 91.245

6.  Apixaban versus warfarin in patients with atrial fibrillation.

Authors:  Christopher B Granger; John H Alexander; John J V McMurray; Renato D Lopes; Elaine M Hylek; Michael Hanna; Hussein R Al-Khalidi; Jack Ansell; Dan Atar; Alvaro Avezum; M Cecilia Bahit; Rafael Diaz; J Donald Easton; Justin A Ezekowitz; Greg Flaker; David Garcia; Margarida Geraldes; Bernard J Gersh; Sergey Golitsyn; Shinya Goto; Antonio G Hermosillo; Stefan H Hohnloser; John Horowitz; Puneet Mohan; Petr Jansky; Basil S Lewis; Jose Luis Lopez-Sendon; Prem Pais; Alexander Parkhomenko; Freek W A Verheugt; Jun Zhu; Lars Wallentin
Journal:  N Engl J Med       Date:  2011-08-27       Impact factor: 91.245

7.  Apixaban with antiplatelet therapy after acute coronary syndrome.

Authors:  John H Alexander; Renato D Lopes; Stefan James; Rakhi Kilaru; Yaohua He; Puneet Mohan; Deepak L Bhatt; Shaun Goodman; Freek W Verheugt; Marcus Flather; Kurt Huber; Danny Liaw; Steen E Husted; Jose Lopez-Sendon; Raffaele De Caterina; Petr Jansky; Harald Darius; Dragos Vinereanu; Jan H Cornel; Frank Cools; Dan Atar; Jose Luis Leiva-Pons; Matyas Keltai; Hisao Ogawa; Prem Pais; Alexander Parkhomenko; Witold Ruzyllo; Rafael Diaz; Harvey White; Mikhail Ruda; Margarida Geraldes; Jack Lawrence; Robert A Harrington; Lars Wallentin
Journal:  N Engl J Med       Date:  2011-07-24       Impact factor: 91.245

8.  Apixaban in patients with atrial fibrillation.

Authors:  Stuart J Connolly; John Eikelboom; Campbell Joyner; Hans-Christoph Diener; Robert Hart; Sergey Golitsyn; Greg Flaker; Alvaro Avezum; Stefan H Hohnloser; Rafael Diaz; Mario Talajic; Jun Zhu; Prem Pais; Andrzej Budaj; Alexander Parkhomenko; Petr Jansky; Patrick Commerford; Ru San Tan; Kui-Hian Sim; Basil S Lewis; Walter Van Mieghem; Gregory Y H Lip; Jae Hyung Kim; Fernando Lanas-Zanetti; Antonio Gonzalez-Hermosillo; Antonio L Dans; Muhammad Munawar; Martin O'Donnell; John Lawrence; Gayle Lewis; Rizwan Afzal; Salim Yusuf
Journal:  N Engl J Med       Date:  2011-02-10       Impact factor: 91.245

9.  Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial.

Authors:  J Donald Easton; Renato D Lopes; M Cecilia Bahit; Daniel M Wojdyla; Christopher B Granger; Lars Wallentin; Marco Alings; Shinya Goto; Basil S Lewis; Mårten Rosenqvist; Michael Hanna; Puneet Mohan; John H Alexander; Hans-Christoph Diener
Journal:  Lancet Neurol       Date:  2012-05-08       Impact factor: 44.182

Review 10.  Dabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: systematic review, meta-analysis, and indirect treatment comparisons.

Authors:  Antonio Gómez-Outes; Ana Isabel Terleira-Fernández; M Luisa Suárez-Gea; Emilio Vargas-Castrillón
Journal:  BMJ       Date:  2012-06-14
View more
  4 in total

Review 1.  Polymeric nanoparticles in the diagnosis and treatment of myocardial infarction: Challenges and future prospects.

Authors:  Mia Karam; Duaa Fahs; Batoul Maatouk; Brouna Safi; Ayad A Jaffa; Rami Mhanna
Journal:  Mater Today Bio       Date:  2022-04-04

2.  Intestinal Efflux Transporters P-gp and BCRP Are Not Clinically Relevant in Apixaban Disposition.

Authors:  Jasleen K Sodhi; Shuaibing Liu; Leslie Z Benet
Journal:  Pharm Res       Date:  2020-09-29       Impact factor: 4.200

Review 3.  Apixaban and oral implications.

Authors:  Monica Lopez-Galindo; Jose V Bagán
Journal:  J Clin Exp Dent       Date:  2015-10-01

Review 4.  Implications of apixaban for dental treatments.

Authors:  Adrian Curto; Alberto Albaladejo
Journal:  J Clin Exp Dent       Date:  2016-12-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.